VEGFRVascular endothelial growth factor receptor

VEGFRs consist of three subtypes the fms-like tyrosine kinase Flt-1 (VEGFR1Flt-1) the kinase domain region also referred to asfetal liver kinase (VEGFR2KDRFlk-1) and Flt-4 (VEGFR3) Each receptor has seven immunoglobulinlike domains in the extracellulardomain a single transmembrane region and a consensus tyrosine kinase sequence interrupted by a kinase insert domain VEGFR1and 2 are expressed on vascular endothelial cells whereas VEGFR3 is expressed on lymphatic endothelial The VEGF familymembers VEGF-A -B -C -D -E and PlGF and the human immunodeficiency (HIV) Tat protein bind in specific patterns to threerelated receptor protein tyrosine kinases VEGFR1 2 and 3 and induce the formation of homo- and heteromeric receptorcomplexes Binding of VEGF to VEGFR causes dimerization and autophosphorylation of the receptor Intracellular proteins such asVEGFR-associated protein (VRAP) PLC and Sck that associate with specific tyrosine residues of VEGFR are phosphorylated uponreceptor activation Several signal transduction pathways are activated by the binding of VEGF to its receptor leading to increasedproliferation survival permeability and migration of cells

wwwMedChemExpresscom 1

VEGFR Inhibitors amp Antagonists

(Rac)-SAR131675Cat No HY-123050

(Rac)-SAR131675 is the racemate of SAR131675SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

(Z)-GuggulsteroneCat No HY-110066

Z-guggulsterone a constituent of Indian Ayurvedicmedicinal plant inhibitsCommiphora mukulthe growth of human prostate cancer cells bycausing Z-guggulsterone inhibitsapoptosisangiogenesis by suppressing the VEGFndashVEGF-R2ndashAktsignaling axis

Purity 9827Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg

(Z)-Orantinib ((Z)-SU6668 (Z)-TSU-68) Cat No HY-10517A

(Z)-Orantinib ((Z)-SU6668) is a potent selectiveorally active and ATP competitive inhibitor of

and with s of 21Flk1KDR PDGFRβ FGFR1 IC50

0008 and 12 microM respectively (Z)-Orantinib isa potent antiangiogenic and antitumor agent thatinduces regression of established tumors

Purity 9902Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

3-Methylthienyl-carbonyl-JNJ-7706621Cat No HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621 is a potentand selective inhibitor of cyclin-dependent kinase

with s of 64 nM and 2 nM for(CDK) IC50

and respectivelyCDK1cyclinB CDK2cyclinA

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

5Z-7-Oxozeaenol (FR148083 L783279 LL-Z 1640-2) Cat No HY-12686

5Z-7-Oxozeaenol is a natural anti-protozoancompound from fungal origin acting as a potentirreversible and selective inhibitor of andTAK1

with s of 8 nM and 52 nMVEGF-R2 IC50

respectively

Purity ge990Clinical Data No Development ReportedSize 1 mg

5α-Hydroxycostic acidCat No HY-N2666

5α-Hydroxycostic acid a eudesmane-typesesquiterpene is isolated from the herb Laggeraalata 5α-Hydroxycostic acid inhibits angiogenesisand suppresses breast cancer cell migrationthrough regulating and VEGFVEGFR2 Ang2Tie2pathways

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Acrizanib (LHA510) Cat No HY-109020

Acrizanib (LHA510) is a inhibitor withVEGFR-2an of 174 nM for BaF3-VEGFR-2IC50

Purity 9984Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg

AG-13958 (AG-013958) Cat No HY-15492

AG-13958 (AG-013958) a potent VEGFR tyrosine inhibitor is used for treatment ofkinase

choroidal neovascularization associated withage-related macular degeneration (AMD)

Purity 9964Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

AhR modulator-1Cat No HY-135671

AhR modulator-1 (compound 6-MCDF) is a selectiveand orally active aryl hydrocarbon receptor (AhR)modulator AhR modulator-1 inhibits metastasis inpart by inhibiting productionprostatic VEGFprior to tumor formation AhR modulator-1 alsopossess anti- properties in rat uterusestrogenic

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Altiratinib (DCC-2701) Cat No HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinaseinhibitor with s of 27 8 92 93 085IC50

46 083 nM for MET TIE2 VEGFR2 FLT3 and respectivelyTrk1 Trk2 Trk3

Purity 9806Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

2 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom

AMG-47aCat No HY-18303

AMG-47a is a potent and orally activelymphocyte-specific protein tyrosine kinase

inhibitor with an of 02 nM AMG-47a(Lck) IC50

also inhibits and andVEGF2 p38α Jak3 MLR with s of 1 nM 3 nM 72 nM 30 nM and 21IL-2 IC50

nM respectively

Purity 9871Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg

AMG-Tie2-1Cat No HY-13023

AMG-Tie2-1 is an inhibitor of tunica interna with an of 1endothelial cell kinase 2 (Tie2) IC50

nM AMG-Tie2-1 is a VEGFR2 inhibitor with an IC50

of 3 nM

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

AST 487 (NVP-AST 487) Cat No HY-15002

AST 487 is a kinase inhibitor with ofRET IC50

880 nM inhibits RET autophosphorylation andactivation of downstream effectors also inhibits

with of 520 nMFlt-3 IC50

Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg

Axitinib (AG-013736) Cat No HY-10065

Axitinib is a multi-targeted tyrosine kinaseinhibitor with s of 01 02 01-03 16 nMIC50

for and VEGFR1 VEGFR2 VEGFR3 PDGFRβrespectively

Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 50 mg 100 mg 200 mg 500 mg

Axitinib-d3 (AG-013736-d3) Cat No HY-10065S1

Axitinib-d3 (AG-013736-d3) is deuterium labeledAxitinib Axitinib is a multi-targeted tyrosinekinase inhibitor with s of 01 02 01-03IC50

16 nM for and VEGFR1 VEGFR2 VEGFR3 respectivelyPDGFRβ

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

AZD2932Cat No HY-18179

AZD2932 is a potent and multi-targeted kinaseinhibitor and withVEGFR2 PDGFβ Flt-3 c-Kit

s of 8 4 7 and 9 nM in cell assayIC50

respectively

Purity 9611Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Bevacizumab (Anti-Human VEGF Humanized Antibody) Cat No HY-P9906

Bevacizumab a humanized monoclonal antibodyspecifically binds to all isoforms withVEGF-Ahigh affinity

Purity 9850Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg

BFH772Cat No HY-100419

BFH772 is a potent oral inhibitor whichVEGFR2is highly effective at targeting VEGFR2 kinasewith an value of 3 nMIC50

Purity 9638Clinical Data Phase 2Size 5 mg 10 mg 25 mg 50 mg 100 mg

BIBF 1202Cat No HY-15992

BIBF 1202 is the carboxylate metabolite of BIBF1120 which inhibits kinase with an ofVEGFR2 IC50

62 nM

Purity 9929Clinical Data No Development ReportedSize 1 mg 5 mg

BMS-690514Cat No HY-10333

BMS-690514 is a potent and orally active inhibitorof and has s of 5 20 and 60 nMEGFR VEGFR IC50

for EGFR HER 2 and HER 4 respectively

Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg

wwwMedChemExpresscom 3

BMS-794833Cat No HY-10497

BMS-794833 is a and inhibitorVEGFR2 Metextracted from patent WO2009094417 compoundexample 1 has s of 15 and 17 nMIC50

respectively

Purity 9978Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Brivanib (BMS-540215) Cat No HY-10337

Brivanib (BMS-540215) is an ATP-competitiveinhibitor against with an of 25 nMVEGFR2 IC50

and has moderate potency against VEGFR-1 andFGFR-1 but gt240-fold against PDGFR-β

Purity 9937Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Brivanib (alaninate) (BMS-582664) Cat No HY-10336

Brivanib alaninate (BMS-582664) is anATP-competitive inhibitor against with anVEGFR2

of 25 nM has moderate potency againstIC50

VEGFR-1 and FGFR-1 but more than 240-fold againstPDGFRβ

Purity 9945Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Cabozantinib (XL184 BMS-907351) Cat No HY-13016

Cabozantinib is a potent multiple receptortyrosine kinases (RTKs) inhibitor that inhibits

and with s ofVEGFR2 c-Met Kit Axl Flt3 IC50

0035 13 46 7 and 113 nM respectively

Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg

Cabozantinib S-malate (XL184 S-malate BMS-907351 S-malate) Cat No HY-12044

Cabozantinib S-malate (XL184 S-malate) is a potentmultiple receptor tyrosine kinases inhibitor thatinhibits and withVEGFR2 c-Met Kit Axl Flt3

s of 0035 13 46 7 and 113 nMIC50

respectively

Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg

Cabozantinib-d6Cat No HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuteriumlabeled Cabozantinib Cabozantinib is a potentmultiple receptor tyrosine kinases (RTKs)inhibitor that inhibits VEGFR2 c-Met Kit Axland with s of 0035 13 46 7 and 113Flt3 IC50

nM respectively

Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg

Cediranib (AZD2171) Cat No HY-10205

Cediranib (AZD2171) is a highly potent orallyavailable tyrosine kinase inhibitor withVEGFR

s of lt1 lt3 5 5 36 2 nM for Flt1IC50

KDR Flt4 PDGFRα PDGFRβ c-Kit respectively

Purity 9958Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg

Cediranib maleate (AZD-2171 maleate) Cat No HY-13049

Cediranib maleate (AZD-2171 maleate) is a highlypotent orally available inhibitor withVEGFR

s of lt1 lt3 5 5 36 2 nM for Flt1IC50

KDR Flt4 PDGFRα PDGFRβ c-Kit respectively

Purity 9974Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Chiauranib (CS2164) Cat No HY-124526

Chiauranib (CS2164) is an orally activemulti-target inhibitor against tumor angiogenesis

Purity 9928Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg

Chloropyramine hydrochlorideCat No HY-B1305

Chloropyramine hydrochloride is a histamine antagonist which can also inhibit thereceptor H1

biochemical function of and VEGFR-3 FAK

Purity 9973Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg

4 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom

CP-547632Cat No HY-13302

CP-547632 is an orally active ATP-competitive andpotent and kinases inhibitor withVEGFR-2 FGF

s of 11 nM and 9 nM respectively CP-547632IC50

is selective for VEGFR2 and bFGF over EGFRPDGFRβ and related tyrosine kinases (TKs)CP-547632 has antitumor efficacy

Purity 9871Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg

CP-547632 hydrochlorideCat No HY-13302B

CP-547632 hydrochloride is an orally activeATP-competitive and potent and VEGFR-2 FGFkinases inhibitor with s of 11 nM and 9 nMIC50

respectively CP-547632 hydrochloride is selectivefor VEGFR2 and bFGF over EGFR PDGFRβ and relatedtyrosine kinases (TKs)

Purity 9824Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg

CP-547632 TFACat No HY-13302C

CP-547632 TFA is an orally active ATP-competitiveand potent and kinases inhibitorVEGFR-2 FGFwith s of 11 nM and 9 nM respectivelyIC50

CP-547632 TFA is selective for VEGFR2 and bFGFover EGFR PDGFRβ and related tyrosine kinases(TKs) CP-547632 TFA has antitumor efficacy

Purity 9942Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg

Dovitinib (CHIR-258 TKI258) Cat No HY-50905

Dovitinib (CHIR-258) is a multi-targeted tyrosinekinase inhibitor with s of 1 2 89 10138IC50

27210 nM for FLT3 c-Kit FGFR1FGFR3 and VEGFR1VEGFR2VEGFR3 PDGFRαPDGFRβ

respectively

Purity 9994Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg

Dovitinib lactate (CHIR-258 lactate TKI-258 lactate) Cat No HY-10207

Dovitinib lactate (TKI258 lactate) is amulti-targeted tyrosine kinase inhibitor with

s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ

respectively

Purity 9996Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg

Dovitinib lactate hydrate (TKI258 lactate hydrate CHIR-258 lactate hydrate) Cat No HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate)is a multi-targeted tyrosine kinase inhibitor with

s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ

respectively

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Dovitinib-D8Cat No HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuteriumlabeled Dovitinib Dovitinib (CHIR-258) is amulti-targeted tyrosine kinase inhibitor with

s of 1 2 89 10138 27210 nM for IC50 FLT3 andc-Kit FGFR1FGFR3 VEGFR1VEGFR2VEGFR3

respectivelyPDGFRαPDGFRβ

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

ENMD-2076Cat No HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitorwith s of 186 14 582 159 927 708IC50

564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src PDGFRα

respectively

Purity 9912Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

ENMD-2076 TartrateCat No HY-10987

ENMD-2076 Tartrate is a multi-targeted kinaseinhibitor with s of 186 14 582 159IC50

927 708 564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src

respectivelyPDGFRα

Purity 9887Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg

EOC317 (ACTB-1003) Cat No HY-16025

EOC317 (ACTB-1003) is an oral kinase inhibitorwith s of 6 2 and 4 nM for IC50 FGFR1 VEGFR2and Tie-2

Purity 9811Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg 100 mg

wwwMedChemExpresscom 5

Foretinib (XL880 GSK1363089 GSK089 EXEL-2880) Cat No HY-10338

Foretinib is a multi-target tyrosine kinaseinhibitor with s of 04 nM and 09 nM forIC50

and Met KDR

Purity 9959Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Fruquintinib (HMPL-013) Cat No HY-19912

Fruquintinib (HMPL-013) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50

33 035 and 35 nM respectively

Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Gandotinib (LY2784544) Cat No HY-13034

Gandotinib (LY2784544) is a potent inhibitorJAK2with of 3 nM Gandotinib (LY2784544) alsoIC50

inhibits FLT3 FLT4 FGFR2 TYK2 and TRKB withIC of 4 25 32 44 and 95 nM50

Purity 9982Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Golvatinib (E-7050) Cat No HY-13068

Golvatinib (E-7050) is a potent dual inhibitor ofboth and kinases with s of 14c-Met VEGFR2 IC50

and 16 nM respectively

Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

GW768505A free baseCat No HY-125741

GW768505A free base is a potent dual inhibitor of and with a p of 781 forVEGFR2 (KDR) Tie-2 IC50

VEGFR2 GW768505A free base has anti-angiogenicactivity

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

GW806742XCat No HY-112292

GW806742X an ATP mimetic and a potent MLKL(Mixed Lineage Kinase Domain-Like protein)inhibitor binds the MLKL pseudokinase domain witha of 93 μM GW806742X has activity againstKd

( =2 nM) GW806742X retards MLKLVEGFR2 IC50

membrane translocation and inhibits necroptosis

Purity 9991Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg

GW806742X hydrochlorideCat No HY-112292A

GW806742X hydrochloride an ATP mimetic and apotent MLKL (Mixed Lineage Kinase Domain-Like

inhibitor binds the MLKL pseudokinaseprotein)domain with a of 93 μM GW806742XKd

hydrochloride has activity against ( =2VEGFR2 IC50

nM)

Purity 9877Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg

hVEGF-IN-1Cat No HY-101931

hVEGF-IN-1 a quinazoline derivative couldspecifically bind to the G-rich sequence in theinternal ribosome entry site A (IRES-A) anddestabilize the G-quadruplex structure hVEGF-IN-1binds to the IRES-A (WT) with a of 0928 μMKd

in SPR experiments

Purity 9831Clinical Data No Development ReportedSize 1 mg 5 mg 10 mg

HypothemycinCat No HY-107417

Hypothemycin a fungal polyketide is amultikinase inhibitor with s of 1070 nM 1738Ki

nM 90 nM 900 nM15 μM and 8424 μM for VEGFR2VEGFR1 MEK1MEK2 FLT-3 and respectivelyPDGFRβPDGFRα ERK1ERK2

Purity ge980Clinical Data No Development ReportedSize 1 mg

Ilorasertib (ABT-348) Cat No HY-16018

Ilorasertib (ABT-348) is a potent andATP-competitive multitargeted kinase inhibitorwhich inhibits and Aurora C Aurora B Aurora

with s of 1 nM 7 nM 120 nM respectivelyA IC50

Purity ge980Clinical Data Phase 2Size 50 mg 100 mg

6 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom

Ilorasertib hydrochloride (ABT-348 hydrochloride) Cat No HY-16018A

Ilorasertib (ABT-348 hydrochloride) is a potentand ATP-competitive multitargeted kinaseinhibitor which inhibits Aurora C Aurora Band with s of 1 nM 7 nM 120 nMAurora A IC50

respectively

Purity 9891Clinical Data Phase 2Size 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg

JI-101Cat No HY-16265

JI-101 is an orally available multi-kinaseinhibitor of and withVEGFR2 PDGFRβ EphB4potent anti-cancer activity

Purity 9943Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

JNJ-38158471Cat No HY-18317

JNJ-38158471 is a well tolerated orallyavailable highly selective inhibitorVEGFR-2with an of 40 nM JNJ-38158471 also inhibitsIC50

and with s of 180 and 500 nMRet Kit IC50

respectively

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

K00546Cat No HY-103647

K00546 is a potent and inhibitor withCDK1 CDK2s of 06 nM and 05 nM for andIC50 CDK1cyclin B

respectively K00546 is also aCDK2cyclin Apotent and CDC2-like kinase 1 (CLK1) CLK3inhibitor with s of 89 nM and 292 nMIC50

respectively

Purity 9878Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Ki20227Cat No HY-10408

Ki20227 is an orally active and highly selective inhibitor withc-Fms tyrosine kinase (CSF1R)

s of 2 nM 12 nM 451 and 217 nM for CSF1RIC50

(vascular endothelial growth factorVEGFR2receptor-2) (stem cell factor receptor) andc-Kit

(platelet-derived growth factorhellipPDGFRβ

Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg

Ki8751Cat No HY-12038

Ki8751 is a potent inhibitor with an VEGFR2 IC50

of 09 nM

Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

KRN-633Cat No HY-12060

KRN-633 is a potent inhibitor with s ofVEGFR IC50

170 160 and 125 nM for VEGFR1 VEGFR2 and VEGFR3respectively

Purity 9937Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Lenvatinib (E7080) Cat No HY-10981

Lenvatinib (E7080) is an oral multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3

and shows potentFGFR1-4 PDGFR KIT RETantitumor activities

Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Lenvatinib mesylate (E7080 mesylate) Cat No HY-10981A

Lenvatinib mesylate (E7080 mesylate) an oralmulti-targeted tyrosine kinase inhibitor thatinhibits andVEGFR1-3 FGFR1-4 PDGFR KIT

shows potent antitumor activitiesRET

Purity 9986Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Linifanib (ABT-869 AL-39324) Cat No HY-50751

Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of and familyVEGFR PDGFRwith s of 4 3 66 and 4 nM for KDR FLT1IC50

PDGFRβ and FLT3 respectively Linifanib showsprominent antitumor activity

Purity 9972Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg

wwwMedChemExpresscom 7

Lucitanib (E-3810) Cat No HY-15391

Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR

inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50

and 825 nM respectively

Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg

MAZ51Cat No HY-116624

MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ

Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg

MGCD-265 analogCat No HY-10991

MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50

respectively MGCD-265 analog has significantantitumor activity

Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg

ML786 dihydrochlorideCat No HY-14979A

ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50

42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Motesanib (AMG 706) Cat No HY-10228

Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50

bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold

more selective for VEGFR than PDGFR and Ret

Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg

Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229

Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50

has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret

Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg

NingetinibCat No HY-107145A

Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50

of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl

Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg

Ningetinib TosylateCat No HY-107145

Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50

nM for and respectivelyc-Met VEGFR2 Axl

Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg

Nintedanib (BIBF 1120) Cat No HY-50904

Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50

nM37 nM108 nM and 59 nM65 nM respectively

Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g

Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123

and with s of 34 nM13FGFR123 PDGFRαβ IC50

nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively

Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg

8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom

NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624

NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β

with s of 038 002 (023) 018 14 μMIC50

respectively

Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg

NVP-BAW2881 (BAW2881) Cat No HY-100394

NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50

Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg

ODM-203Cat No HY-119367

ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50

recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity

Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg

Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718

Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth

Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections

Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Orantinib (SU6668 TSU-68) Cat No HY-10517

Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki

μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively

Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

OSI-930Cat No HY-10204

OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50

nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity

Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg

Pamufetinib (TAS-115) Cat No HY-12423

TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50

and rMET respectively

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Pazopanib (GW786034) Cat No HY-10208

Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ

and with s of 10 30c-Kit FGFR1 c-Fms IC50

47 84 74 140 and 146 nM respectively

Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg

Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1

andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50

and 146 nM respectively

Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg

PD173074Cat No HY-10321

PD173074 is a potent inhibitor with an FGFR1 IC50

of 25 nM and also inhibits with an ofVEGFR2 IC50

100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src

Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg

wwwMedChemExpresscom 9

Pentagamavunon-1 (PGV-1) Cat No HY-136477

Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB

Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

PF 477736 (PF 00477736) Cat No HY-10032

PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki

049 nM it is also a inhibitor with a Chk2 Ki

of 47 nM

Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg

PF-03814735Cat No HY-14574

PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A

inhibitor with s of 08 and 05 nMaurora B IC50

respectively

Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg

Ponatinib (AP24534) Cat No HY-12047

Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50

nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src

Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

Ponatinib D8 (AP24534 D8) Cat No HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50

nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

PP121Cat No HY-10372

PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR

respectivelyDNK-PK VEGFR2 Src PDGFR

Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

PTC299Cat No HY-124593

PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation

protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of

dihydroorotate dehydrogenase (DHODH)

Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg

Pz-1Cat No HY-U00437

Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50

kinases

Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg

R1530Cat No HY-13737

R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd

Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg

R916562Cat No HY-104075

R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50

nM respectively R916562 has anti-angiogenesisand anti-metastasis

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom

RAF265 (CHIR-265) Cat No HY-10248

RAF265 is a potent inhibitorRAF VEGFR2

Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg

RamucirumabCat No HY-P9920

Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D

Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg

Ranibizumab (RG-6321) Cat No HY-P9951

Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research

Purity 9860Clinical Data LaunchedSize 1 mg

Regorafenib (BAY 73-4506) Cat No HY-10331

Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50

134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1

Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S

Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308

Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for

and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50

respectively

Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A

Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123

and with s ofPDGFRβ Kit RET Raf-1 IC50

134246 22 7 15 and 25 nM respectively

Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg

Ripretinib (DCC-2618) Cat No HY-112306

Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA

Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

SAR131675Cat No HY-15458

SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50

Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg

SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A

SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor

Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

wwwMedChemExpresscom 11

Semaxinib (SU5416) Cat No HY-10374

Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50

123 μM

Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg

Sitravatinib (MGCD516 MG-516) Cat No HY-16961

Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)

s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50

nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively

Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg

Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A

Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50

6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively

Purity gt98Clinical Data Phase 3Size 1 mg 5 mg

Sorafenib (Bay 43-9006) Cat No HY-10201

Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50

for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50

nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit

Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg

Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S

Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50

Raf-1 B-Raf and VEGFR-3 respectively

Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg

Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1

Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50

Raf-1 B-Raf and VEGFR-3 respectively

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A

Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50

of 6 nM and 20 nM for and Raf-1 B-Rafrespectively

Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg

SU 5402Cat No HY-10407

SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50

nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively

Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

SU14813Cat No HY-10501

SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50

for and VEGFR2 VEGFR1 PDGFRβ KIT

Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg

SU14813 maleateCat No HY-10501A

SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50

15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT

Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg

12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom

SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326

SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50

700 nM

Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg

SU4312Cat No HY-100349

SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50

(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50

100 μM respectively

Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg

SU5204Cat No HY-126319

SU5204 a tyrosine kinase inhibitor has s ofIC50

4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively

Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg

SU5205Cat No HY-21289

SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50

Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg

SU5208Cat No HY-136209

SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

SU5214 (SU4949) Cat No HY-21292

SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50

microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR

Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg

SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002

SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2

of 70 nMIC50

Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg

Sulfatinib (HMPL-012) Cat No HY-12297

Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against

and with s of in aVEGFR123 FGFR1 CSF1R IC50

range of 1 to 24 nM

Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg

Sunitinib (SU 11248) Cat No HY-10255A

Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50

2 nM for and respectivelyVEGFR2 PDGFRβ

Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg

Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS

Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50

80 nM and 2 nM for and VEGFR2 PDGFRβrespectively

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

wwwMedChemExpresscom 13

Sunitinib Malate (SU 11248 Malate) Cat No HY-10255

Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2

respectivelyPDGFRβ

Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg

Sunitinib-d4Cat No HY-10255AS1

Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2

respectivelyPDGFRβ

Purity gt98Clinical DataSize 25 mg 1 mg 25 mg

TAK-593Cat No HY-15506

TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50

nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively

Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135

Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of

VEGF VEGFR2

Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg

TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A

TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50

rVEGFR2 and rMET respectively

Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Telatinib (Bay 57-9352) Cat No HY-10527

Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50

respectively

Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C

Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50

and 1 nM respectively

Purity gt98Clinical Data Phase 2Size 1 mg 5 mg

Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314

Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4

kinase with s of 03 16 15 87 andEphB4 IC50

14 nM

Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg

TG 100572Cat No HY-10184

TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src

has s of 2 7 2 16 13 5 05 6kinases IC50

01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

TG 100572 HydrochlorideCat No HY-10185

TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50

05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively

Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg

14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom

TG 100801Cat No HY-10186

TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration

Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg

TG 100801 HydrochlorideCat No HY-10187

TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration

Purity gt98Clinical Data Phase 2Size 1 mg 5 mg

TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294

TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis

Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg

TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572

TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50

856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Tivozanib (AV-951 KRN951) Cat No HY-10977

Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50

021 016 and 024 nM in cell assayrespectively

Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg

Toceranib (SU11654 PHA 291639E) Cat No HY-10330

Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR

and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki

and Flk-1KDR respectively

Purity 9625Clinical Data LaunchedSize 10 mg 50 mg

Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A

Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR

and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki

and Flk-1KDR respectively

Purity 9802Clinical Data LaunchedSize 10 mg 50 mg

Toceranib-d8Cat No HY-10330S

Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki

of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively

Purity gt98Clinical DataSize 1 mg 10 mg

Tyrosine kinase-IN-1Cat No HY-100315

Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50

and respectivelyKDR Flt-1 FGFR1 PDGFRα

Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg

Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511

Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has

activitiesanti-influenza virus

Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg

wwwMedChemExpresscom 15

Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757

Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ

inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50

and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation

Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

Vandetanib (ZD6474) Cat No HY-10260

Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50

the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50

Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg

Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B

Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50

hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50

nM) and ( =500 nM)EGFRHER1 IC50

Purity gt98Clinical Data LaunchedSize 1 mg 5 mg

Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A

Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50

Purity gt98Clinical Data LaunchedSize 1 mg 5 mg

Vandetanib-d4Cat No HY-10260S1

Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50

Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg

Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870

dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018

Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50

Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg

Vatalanib free base (PTK787 free base PTKZK free base

CGP-79787 free base ZK-222584 free base) Cat No HY-10203

Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50

Purity gt98Clinical Data Phase 3Size 1 mg 5 mg

Vatalanib-d4 dihydrochlorideCat No HY-12018S

Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50

Purity gt98Clinical DataSize 1 mg 10 mg

VEGFR-2-IN-5Cat No HY-18625

VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69

Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg

VEGFR-2-IN-5 hydrochlorideCat No HY-18625A

VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69

Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom

VEGFR-2-IN-6Cat No HY-131658

VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110

Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg

VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628

VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

VEGFR-3-IN-1Cat No HY-132305

VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

Vorolanib (CM082 X-82) Cat No HY-109019

Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)

Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

WHI-P180 (Janex 3) Cat No HY-15769

WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50

66 nM and 4 μM respectively

Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg

WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A

WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50

66 nM and 4 μM respectively

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

XanthatinCat No HY-N3032

Xanthatin is isolated from Xanthium leavesstrumarium

Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg

ZD-4190Cat No HY-U00002

ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer

Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg

ZK-261991Cat No HY-15333

ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

ZM 306416 (CB 676475) Cat No HY-13785

ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50

respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50

Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg

wwwMedChemExpresscom 17

ZM323881Cat No HY-15467

ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50

Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg

ZM323881 hydrochlorideCat No HY-15467A

ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50

Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg

18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom